Key result
Revacept is a novel, lesion-directed antithrombotic drug that inhibits collagen-mediated platelet adhesion and aggregation at the site of vascular injury without increasing bleeding risk.
Why the study?
Does Revacept prevent ischemic events and restenosis without increasing bleeding in patients with cardiovascular disease?
Does Revacept prevent ischemic events and restenosis without increasing bleeding in patients with cardiovascular disease?
Revacept is a promising lesion-specific antiplatelet agent that targets GPVI to prevent thrombosis and restenosis without increasing bleeding risk.
Revacept's safety profile may justify phase 3 trials; leaves open efficacy versus standard therapy in CAD.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Contursi et al. (2022) conducted a review in Cardiovascular disease. Revacept was evaluated. Revacept is a novel, lesion-directed antithrombotic drug that inhibits collagen-mediated platelet adhesion and aggregation at the site of vascular injury without increasing bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: